FDA direction on e-cigarettes up in the air after Gottlieb resignation

The FDA’s continued crackdown of the vaping and e-cigarette industry is questionable after the resignation of its commissioner Scott Gottlieb, who announced March 5 he would depart sometime in the next month.

The agency had been pursuing an aggressive campaign to limit youth access to vapor tobacco products, such as e-cigarettes, by potentially banning flavored nicotine. However, the work was left undone as Gottlieb announced his departure, according to The Hill.

“But none of the proposals have been implemented, and it’s not known whether his eventual replacement will follow the same strategy,” The Hill reported.

Gottlieb’s stance on vaping products has been harsh, even threatening to ban such products altogether. Some studies have shown that e-cigarettes can be a helpful tool to drop traditional smoking. In the aftermath of Gottlieb’s resignation, tobacco stocks rose, according to The Hill. A replacement has not yet been named.

The American Heart Association (AHA) has publicly urged the agency to continue its crackdown on the vaping industry in the aftermath of the resignation.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.